Zoetis Inc(NYSE:ZTS) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 3, 2016. Company reported revenue of $1.21B. Analysts estimated a revenue of $1.17B. Earnings per share were $0.49. Analysts had estimated an EPS of $0.44.
In a different note, On Jun 14, 2016, Jefferies said it Maintains its rating on Zoetis Inc. In the research note, the firm Raises the price-target to $57.00 per share. The shares have been rated ‘Buy’ by the firm. On Jun 10, 2016, Citigroup said it Downgrades its rating on Zoetis Inc. In the research note, the firm Raises the price-target to $46.00 per share. The shares have been rated ‘Neutral’ by the firm. Stifel Nicolaus said it Initiates Coverage on Zoetis Inc, according to a research note issued on Jun 1, 2016. The shares have been rated ‘Buy’ by the firm. On May 6, 2016, Goldman Sachs said it Downgrades its rating on Zoetis Inc. In the research note, the firm Raises the price-target to $46.00 per share. The shares have been rated ‘Sell’ by the firm.
Zoetis Inc (ZTS) shares turned negative on Fridays trading session with the shares closing down -0.09 points or -0.17% at a volume of 19,80,656. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $52.1. The peak price level was also seen at $52.1 while the days lowest was $51.7. Finally the shares closed at $51.98. The 52-week high of the shares is $52.18 while the 52-week low is $37.73. According to the latest information available, the market cap of the company is $25,732 M.
Zoetis Inc. is engaged in the discovery development manufacture and commercialization of animal health medicines and vaccines with a focus on both livestock and companion animals. The Company markets products across four regions: the United States Europe/Africa/Middle East Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle swine poultry sheep and fish and the companion animal species of dogs cats and horses and five product categories: anti-infectives vaccines parasiticides medicated feed additives and other pharmaceutical products. In addition its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.